Followers | 3175 |
Posts | 208744 |
Boards Moderated | 2 |
Alias Born | 02/04/2004 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, January 20, 2018 9:37:29 AM
Unfortunately they no longer have the luxury of any relevant time on their side IMO. So it's my belief that now we know that they're giving a timeline of sometime in the 1st half of 2018 to initiate PODRAS trials that they will not be able to launch those trials ahead of their next offering. I also believe that since they can't even get a meeting with the FDA to go over their HAP studies protocol on their Oxy NDA candidate, that their backs are against the wall on launching those oral and nasal studies prior to their next required offering as well.
And I definitely believe that the FDA is just gonna continue delaying any potential approvals of their Pristiq or Lamictal ANDA's which again puts their backs against the wall on when they'll need to do their next financing offering. Hell even with approvals on these 2 ANDA's, we already know the results of MNK's commercialization endeavors will be a huge disappointment, just as MNK's results on SeroquelXR have been...because MNK continues to try to sell their generics division with no suitors remaining(but 1) to even give them a good offer I might add.
Hey I would love to be proven overly pessimistic at this point...but since we've had since 2009 to see how this company operates and especially how the FDA treats them...to me the fear of when they'll need to do their next financing is real and becoming closer by the day...and if they do have to initiate another offering the market's gonna punish them again and the likelihood of a reverse split becomes the number 1 force driving the negative sentiment(remember the downward pressure from last autumns offering is coming soon too as the 6 month vesting period on those shares expires soon and those shares will surely be immediately dumped as soon as the restriction comes off)...and if a r/s occurs due to the pressure of another offering and IPCI deciding they want to keep their NAZ listing...even good news finally arriving isn't gonna do jack for this stock for at least another 18 to 24 months...and I very much doubt many already long suffering longs are gonna want to stick around and endure 2 more years of pain.
Nothing would please me more than IPCI regaining market and shareholder confidence and this stock trading well above $1 per share again...but to say I'm disappointed on where they're at on their HAP studies and PODRAS trials is putting it mildly. And if IPCI does have to do another financing soon and a reverse split...it's going to be a minimum 2 full years before any long suffering long even has a chance of getting back to the pre reverse split share price levels of $2.50 per share.
Heck all we gotta do is look at PTIE's post reverse split action to see that even with the recent good news on their REMOXY oral & nasal studies...PTIE's post r/s share price is still not back to the pre-reverse split share price levels to know where my pessimism originates if IPCI decides they have to reverse split soon glty
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
UC Asset announces plan of management stock buyback • UCASU • Sep 3, 2024 9:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM